Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT07824323

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Taipei Medical University Hospital (from the registry)
Registry
  • NCT NCT07824323
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07824323. Randomized; single masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2028-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
Acronym
EARLY-BIRD ACS
Condition
Acute Coronary Syndromes
Condition
Dyslipidemia
Intervention (Drug)
bempedoic acid
Intervention (Drug)
Ezetimibe
Intervention (Drug)
High-Intensity Statin Therapy
Lead sponsor
Taipei Medical University Hospital (class: other)

Record details

Record id
cardio:ct-nct07824323
Content hash
c0c86c91621c5238d200feee6b4513da244c990abdbf94fd5d470893710653b6